Durvalumab After chemoRadioTherapy for NSCLC patients Collaborative partners

Astra Zeneca

Pharmaceutical company providing durvalumab and support for some analyses (www.astrazeneca.no) 

Clinical hospitals including patients to the trial (local PI)

Oslo University Hospital, Oslo, Norway (Åslaug Helland)

St. Olavs Hospital, Trondheim, Norway (Bjørn Henning Grønberg)

University Hospital in North of Norway, Tromsø, Norway (Nina Helbekkmo)

Haukeland University Hospital, Bergen, Norway (Marianne Aanerud) 

Stavanger University Hospital, Stavanger, Norway (Tesfaye Madebo)

Oulu University Hospital, Oulu, Finland (Jussi Koivunen)

Tampere University Hospital, Tampere, Finland (Jarkko Ahvonen)

Turku University Hospital, Turku, Finland (Maria Silvoniemi)

National Cancer Institute, Vilnius, Lithuania (Saulius Cicenas)

Northern Estonia Medical Centre, Tallin, Estonia (Kersti Oselin)

Research partners at Oslo University Hospital

Cecilie E Kiserud, head of The National Advisory Unit for Late Effects After Cancer:

Hege G Russnes, MD head of Molecular pathology for clinical studies

Jon Amund Kyte, MD Group leader Dept of Cancer Immunology and Head of Clinical Trial Unit

Eirik Malinen, Professor of biophysics and medical physics, University of Oslo and OUH

Tero Aittokallio, head of Computational Systems Medicine in cancer

Johannes E.R Hov MD group leader, Marius Trøseid MD group leader, Leaders of Regional Research Network for Clinical Microbiota Science